Mast cells are an exceptionally rich source of prostaglandin D 2 (PGD 2 ). PGD 2 is pro-inflammatory and can cause bronchoconstriction. The enzyme cyclooxygenase (COX) is central to the generation of prostanoids such as PGD 2 . Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit COX. COX exists as two isoforms, COX-1 and COX-2. The principal aim of this study was to establish whether COX-1 and/or COX-2 mediates PGD 2 generation from human lung mast cells. Mast cells were isolated from human lung tissue and purified by flotation over Percoll and immunomagnetic bead separations. The cells were activated with anti-IgE or Stem Cell Factor (SCF). The generation of PGD 2 was determined by ELISA. The effects of NSAIDs (aspirin, ibuprofen, diclofenac, naproxen, indomethacin), COX-1 selective (FR122047), and COX-2 selective (celecoxib) inhibitors on PGD 2 generation were determined. The expression of COX-1 and COX-2 in mast cells was determined by Western blotting. All the NSAIDs tested abrogated stimulated PGD 2 generation from mast cells except aspirin which was only weakly effective. FR122047 was an effective inhibitor of PGD 2 generation (EC 50~2 5 nM) from mast cells whereas celecoxib was ineffective. Immunoblotting indicated that COX-1 was strongly expressed in all mast cell preparations while COX-2 expression was weak. No induction of COX-2 was observed following activation of mast cells. These findings indicate that COX-1 is the principal isoform involved in generating PGD 2 from human lung mast cells. These studies provide insight into the potential behaviour of NSAIDs in the context of respiratory diseases.
Introduction
Mast cells are a very rich source of the prostanoid, PGD 2 (Lewis et al., 1982) . Since very few other cells have the capacity to produce PGD 2 , the presence of PGD 2 or its metabolites is likely to be indicative of mast cell activation (Bochenek et al., 2004; Dahlén and Kumlin, 2004) . PGD 2 mediates bronchoconstriction and is largely pro-inflammatory (Beasley et al., 1987; Matsuoka et al., 2000) . Together with other mast cell derived mediators such as histamine and cysteinylleukotrienes (cys-LTs), PGD 2 contributes to allergic type reactions (Bingham and Austen, 2000; Bradding et al., 2006) . While the recognition that human lung mast cells produce PGD 2 has been acknowledged for some time, the pathway leading to PGD 2 generation in these cells has not been clearly delineated.
The enzyme cyclooxygenase (COX) is central to the generation of prostanoids (Rouzer and Marnett, 2009) . COX converts arachidonic acid to a highly labile intermediate, PGH 2 . Specific synthases then convert PGH 2 into prostanoids. Whereas COX is found widely, synthases tend to show more restricted distribution (Ueno et al., 2005) .
Other than PGD 2 , important prostanoids include PGE 2 , PGF 2α , PGI 2 , and TXA 2 (Woodward et al., 2011) . These display varying profiles of activity. For example, PGE 2 is known to inhibit acid secretion from parietal cells in the gut and also appears to be important in mediating inflammation and sensitizing sensory neurones to pain (Tilley et al., 2001; Peskar et al., 2003; Woodward et al., 2011) .
Non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin and ibuprofen, target COX and, by attenuating prostanoid generation, are useful for the treatment of certain types of inflammation and pain (Cryer and Feldman, 1998) . COX is known to exist as two isoforms COX-1 and COX-2. COX-1 is recognised as the isoform that is expressed constitutively whereas COX-2 is thought to be the form that is induced during inflammation (Mitchell et al., 1994; Cryer and Feldman, 1998; Chan et al., 1999; Warner et al., 1999) . However, constitutive expression of COX-2 may also occur in certain tissues indicating that this isoform cannot solely be considered an inducible form of the enzyme (Kirkby et al., 2016) . Aspirin and ibuprofen are somewhat non-selective drugs and affect both isoforms of COX (Mitchell et al., 1994; Cryer and Feldman, 1998; Chan et al., 1999; Warner et al., 1999) . Any anti-inflammatory benefit of non-selective NSAIDs may therefore be accompanied by non-target effects including inhibition of COX-1 in the gut, leading to a reduction in the production of PGE, increased acid secretion and potential gastropathy (Warner et al., 1999) . Since many NSAIDs show limited selectivity for either COX-1 or COX-2, this has led to the development of COX-2 selective drugs such as celecoxib that are less likely to target COX-1 and are gut-sparing (Chan et al., 1999; Warner et al., 1999; FitzGerald and Patrono, 2001) .
Despite the undoubted value of NSAIDs in the treatment of certain types of inflammation and moderate pain, the use of aspirin and related compounds is largely contraindicated in individuals with asthma and respiratory diseases. This is because aspirin can induce exacerbations in a sizeable proportion of asthmatics (Kowalski et al., 2011) . The mechanism behind this underlying susceptibility to aspirin and related drugs has not been elucidated but aspirin intolerance has been linked to increased production of both cys-LTs and PGD 2 (O'Sullivan et al., 1996; Cahill et al., 2015) . The production of PGD 2 suggests that mast cells are central to the process. While an expectation would be that NSAIDs are likely to inhibit PGD 2 generation from human lung mast cells, there are suggestions that aspirin might activate mast cells by mechanisms that are not clearly understood (Steinke et al., 2014) .
To date, no systematic evaluation of the effects of NSAIDs on human lung mast cells has been performed. The present study aims to redress this. Studies in rodent cell systems and in cultured human mast cells suggest that both COX-1 and COX-2 may contribute to PGD 2 production (Murakami et al., 1995; Reddy and Herschman, 1997; Obata et al., 1999) . However, it is well recognised that mast cells isolated from different species and different sites from the same species display a great deal of heterogeneity (Pearce, 1983; Lowman et al., 1988) . The principal aim of this study, therefore, was to identify which isoform(s) of COX mediates PGD 2 generation from human lung mast cells. The findings of this study may help to explain the actions and behaviour of NSAIDs in the context of respiratory disease.
Materials & methods

Buffers
Phosphate buffered saline (PBS) was employed in these studies. PBS contained (mM): NaCl 137; Na 2 HPO 4 ·7H 2 O 8; KCl 2.7; KH 2 PO 4 1.5. +PBS was PBS supplemented with: CaCl 2 ·2H 2 O 1 mM; MgCl 2 ·6H 2 O 1 mM; glucose 5.6 mM; human serum albumin (HSA) 30 µg/ml. The pH of PBS buffers was titrated to 7.3.
Preparation of compounds
Aspirin, naproxen, diclofenac, ibuprofen, indomethacin, FR122047, celecoxib and wortmannin were prepared as stock solutions (10 mM) in ethanol and stored at -20°C in appropriate aliquots. Stem Cell Factor (SCF) was prepared as a stock solution (100 µg/ml) in water and stored frozen in small aliquots. Monoclonal anti-human IgE antibody (2 mg/ ml stock) was stored frozen over the long-term but a working stock was kept at 4°C for up to a month.
Lung tissue
Lung tissue was obtained following surgery. Seventy-seven lung preparations were used in this study, 42 preparations were derived from males and 35 from females. The age range of participants was 28-89 years with a median age of 72. Informed written consent was obtained. This study was approved by the National Research Ethics' Service (REC reference: 15/NW/0657).
Cell isolation
Mast cells were isolated from human lung tissue using methods described in detail elsewhere (Lewis et al., 2013) . Macroscopically normal tissue from resections was disrupted physically and enzymatically (collagenase Ia) to generate a mixed cell suspension of which 3-13% of the cells were mast cells. Mast cells were visualized by microscopy using an alcian blue stain. This method generated approximately 6 x 10 5 mast cells per g of tissue. Mast cells of enhanced purity 10-69% purity; median 35%) were generated by flotation over discontinuous Percoll gradients (Weston et al., 1997) . Mast cells were further purified using a MACS magnetic cell sorting system (Miltenyi Biotec, Surrey, UK) according to the manufacturer's instructions and as described in detail elsewhere (Havard et al., 2011) . Mast cell purities using this method ranged from 88% to 98% (median 90%). When longer term incubations (4 or 20 h) were necessary, cells were reconstituted in RPMI-1640 buffer supplemented with penicillin (10 Units/ ml), streptomycin (10 μg/ml), gentamicin (50 μg/ml) fungizone (1 μg/ ml) and FBS (5%).
Mediator release
Mediator release experiments were performed essentially as described elsewhere (Lewis et al., 2013) . Experiments were performed in +PBS buffer. Mediator release was initiated either with a mouse antiIgE or SCF. Human lung mast cells express endogenous IgE so the cells are responsive to anti-IgE without the need for passive sensitization with exogenously added IgE (Lewis et al., 2017) . SCF was used in this study as a non-IgE-dependent activator that has previously been shown to be an effective driver of PGD 2 generation from human lung mast cells (Lewis et al., 2013) . When COX inhibitors were used, the cells were incubated for 15 min with the inhibitor before challenge with stimulus. Wortmannin, a PI3K inhibitor, was also included in certain experiments acting as a positive inhibitory control. Histamine released into supernatants was measured using an automated fluorometric method (Ennis, 1991) . Total histamine content was determined by lysing aliquots of the cells with perchloric acid at a final concentration of 1.6%. Cells incubated in buffer alone served as a measure of spontaneous histamine release which ranged from 2% to 8% of the total histamine content. Histamine release was thus expressed as a percentage of the total histamine content after subtracting the spontaneous histamine release. PGD 2 and cys-LT content in the supernatants were determined using commercially available kits (Cayman Chemical Company, Ann Arbor, MI, USA). All experiments were performed in duplicate.
RT-PCR
RNA was extracted from purified mast cells using Tri-Reagent (1 ml). In order to generate cDNA, samples were processed essentially as described (Kay et al., 2013) . Amplification of cDNA was performed by PCR using a modification of the conditions and primer pairs for human COX-1 and COX-2 described elsewhere (Picado et al., 1999) . The house-keeping gene, β-actin, was also amplified. Primers were synthesised by Sigma (Poole, UK). PCR primers used in this study can be found in Table S1 (Supporting Information repository). PCR products were sequenced in-house to ensure that correct amplification had taken place as described in more detail elsewhere (Kay et al., 2013) .
Immunoblotting
Cell extracts were prepared for use in immunoblotting using a lysis buffer (Tris 50 mM; NaCl 150 mM; PMSF 50 µg/ml; SBTI 50 µg/ml; leupeptin 5 µg/ml; aprotinin 5 µg/ml; Triton X-100 0.5%; pH 8.0) according to methods described elsewhere (Fruman et al., 1992) . Cell lysates were prepared for electrophoresis as described (Havard et al., 2011) . Samples were subjected to SDS-PAGE (Mini-Sub Cell GT System; Bio-Rad, Hemel Hempstead, UK) using either 10 or 12% gels and then the separated proteins transferred electrophoretically to nitrocellulose membranes. Membranes were probed with a goat polyclonal antibody to COX-2 followed by secondary antibody (donkey anti-goat IgG-HRP). The membrane was stripped (0.2 M NaOH, 15 min) and probed with a rabbit polyclonal antibody to actin followed by secondary antibody (goat anti-rabbit IgG-HRP). The membrane was stripped again and probed with goat polyclonal antibody for COX-1 followed by secondary antibody (donkey anti-goat IgG-HRP). Using a similar approach, the expression of lipocalin-type PGD synthase (L-PGDS) and haematopoeitic-type PGDS (H-PGDS) was also evaluated in mast cells. Protein bands were visualized by the addition of enhanced chemiluminescence (ECL) reagents and signals detected on ECL film. Membranes were visualized using a BioRad ChemiDoc imaging system (Bio-Rad, Watford, UK).
Materials
The following were purchased from the sources indicated; aspirin, collagenase, DNase, HSA, ibuprofen, indomethacin, Percoll (Sigma, Poole, UK); gentamicin, penicillin/streptomycin, fungizone, RPMI 1640 (Invitrogen, Paisley, UK); diclofenac, FR122047, naproxen (Cayman Chemical Company, Ann Arbor, MI, USA); wortmannin (Calbiochem, Nottingham, UK); celecoxib (BioVision, Milpitas, CA, USA); anti-human IgE, clone HP6061 (Stratech Scientific Ltd, Newmarket, UK); SCF (Peprotech, Rocky Hill, NJ, USA); ECL reagents, nitrocellulose membranes (GE Healthcare Life Sciences, Little Chalfont, UK). All primary and secondary antibodies were purchased from Santa Cruz Biotechnology (Heidelberg, Germany) with the exception of rabbit polyclonal antibody to actin (Sigma, Poole UK) and goat anti-rabbit IgG-HRP (Dako/Agilent, Santa Clara, CA, USA). All other reagents were from Sigma (Poole, UK).
Data analysis
Potencies (EC 50 ) were determined by non-linear regression analysis (GraphPad Prism, version 5.0d). Statistical significance was assessed utilising repeated measures ANOVA. When appropriate post hoc analysis was performed using Dunnett's test.
Results
Effects of COX inhibitors on PGD 2 generation
The effects of a range of commonly used NSAIDs on PGD 2 generation from human lung mast cells were investigated. The concentration (1 µM) of NSAIDs used in these preliminary experiments was considered to be maximally effective based on previous studies (Mitchell et al., 1994; Cryer and Feldman, 1998; Chan et al., 1999; Warner et al., 1999) . IgE-dependent PGD 2 generation was inhibited effectively by naproxen, ibuprofen and diclofenac (Fig. 1A ). These same inhibitors had no effect on either IgE-dependent cys-LT generation (Fig. 1B) or histamine release (Fig. 1C) . By contrast, in these same experiments, aspirin was an ineffective inhibitor of PGD 2 generation, and also had no effect on either cys-LT generation or histamine release. Further studies demonstrated that a higher concentration (10 µM) of aspirin could inhibit PGD 2 generation (Table 1) but the inhibition was far from complete (~38% inhibition) unlike the alternative NSAIDs studied which essentially abolished PGD 2 generation (Fig. 1A) .
Previous clinical studies (O'Sullivan et al., 1996; Cahill et al., 2015) and in vitro studies using peripheral blood derived mast cells (Steinke et al., 2014) suggest that aspirin may directly activate mast cells. However, in this study, we were unable to demonstrate that aspirin or alternative NSAIDs were capable of inducing mediator release from human lung mast cells.
In further studies the effects of FR122047 (COX-1 selective) and celecoxib (COX-2 selective) as well as the NSAID, indomethacin, on PGD 2 generation from human lung mast cells were investigated. The PI3K inhibitor, wortmannin, was included in these experiments as a Mast cells were incubated (15 min) without (-) or with aspirin before challenge for a further 25 min with anti-IgE for mediator release. Values are means ± S.E.M., for 5 different mast cell preparations. Statistically significant reduction in PGD 2 generation compared to control (-) is indicated. * P < 0.05. European Journal of Pharmacology 819 (2018) 225-232 positive inhibitory control. Both indomethacin and FR122047 were effective inhibitors of PGD 2 generation induced by anti-IgE whereas celecoxib was ineffective ( Fig. 2A) . None of the COX inhibitors had much of an effect on the generation of cys-LTs (Fig. 2B) or release of histamine (Fig. 2C ). Previous studies have demonstrated an increase in the mast cell growth factor, SCF, in asthma (Al-Muhsen et al., 2004; Kowalski et al., 2005; Da Silva et al., 2006) . A recent study of ours has shown that SCF is also an effective driver of mediator release from human lung mast cells especially PGD 2 generation (Lewis et al., 2013) . The effects of FR122047 and celecoxib as well as indomethacin on PGD 2 generation driven by SCF from human lung mast cells were investigated. Both FR122047 and indomethacin were very effective inhibitors of PGD 2 generation whereas celecoxib was ineffective (Fig. 3A) . None of the COX inhibitors had any effect on the SCF-induced generation of cys-LTs (Fig. 3B) or release of histamine (Fig. 3C) .
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Further studies were performed with FR122047 using an extended concentration range (10 -11 -10 -6 M). FR122047 inhibited PGD 2 generation by either anti-IgE or SCF in a concentration-dependent manner (Fig. 4) . FR122407 was slightly more potent as an inhibitor of PGD 2 generation induced by SCF than anti-IgE (EC 50 for FR122047 of 9 and 38 nM, respectively).
Expression of COX isoforms by mast cells
RT-PCR was performed in order to determine whether mast cells express message for COX-1 and/or COX-2 (Fig. 5) . The data demonstrate that mast cells express mRNA for both COX-1 and COX-2. Further studies were performed to determine expression of COX-1 and COX-2 at the protein level. The data show that, overall, mast cells strongly express COX-1 and weakly express COX-2 (Fig. 6 ).
Effects of longer-term activation of mast cells on PGD 2 generation
In further studies, we investigated whether longer-term activation of mast cells influenced PGD 2 generation. Mast cells were activated with either anti-IgE or SCF for discrete time intervals (0.5-4 h) and PGD 2 generation monitored. The data show that PGD 2 generation showed no time-dependency when the cells were activated with antiIgE (Fig. 7A) whereas when the cells were activated with SCF (Fig. 7B ), significantly (P < 0.05) more PGD 2 (more than twice as much) was generated at 4 h compared to 30 min.
Experiments were then performed to determine whether this effect of SCF might be related to the up-regulation of COX isoforms. Treatment with SCF (4 or 20 h) had no effect on the expression of either COX-1 or COX-2 (Fig. 8A, B) . We also investigated whether LPS was able to affect COX expression in mast cells since our own studies demonstrate that LPS is a strong inducer of COX-2 in lung macrophages (Fig. S1, Supporting Information repository) . However our data show that LPS has no effect on COX expression in human lung mast cells (Fig. 8B) .
We also investigated whether mast cell activation might lead to upregulation of PGDS expression by mast cells. Mast cells expressed haematopoeitic-type but not lipocalin-type PGDS, the latter synthase more usually associated with the central nervous system (Fig. 8C) . Following activation with SCF (4 or 20 h) or LPS (20 h) there was no increase in expression of either of these synthases (Fig. 8A, C) . . Time-dependence of PGD 2 generation. Mast cells were incubated for between 30 min and 4 h with either (A) anti-IgE (2 µg/ml) or (B) SCF (100 ng/ml) after which PGD 2 generation was assessed. Values are means ± S.E.M., for 4 different mast cell preparations. There was significantly greater generation of PGD 2 after 4 h with SCF compared to a 30 min challenge, *P < 0.05.
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Discussion
In the present study, we have assessed the effects of a variety of COX inhibitors and investigated COX expression in human lung mast cells. Taken together, these studies indicate that COX-1 is the principal isoform responsible for PGD 2 generation in these cells.
Studies with COX-selective inhibitors were particularly informative. That FR122047 abolished IgE-dependent PGD 2 generation provided strong evidence that COX-1 is responsible for the production of PGD 2 in human lung mast cells. FR122047 inhibits human recombinant COX-1 with an IC 50 of~30 nM and is about 2000 fold more potent against COX-1 than COX-2 (Ochi et al., 2000) . The potency of FR122047 (EC 50 25 nM) as an inhibitor of PGD 2 generation from human lung mast cells was very much in keeping with an effect at COX-1. By contrast, that celecoxib was unable to inhibit PGD 2 argues against a role for COX-2. It should be noted that although celecoxib shows some modest selectivity for COX-2 over COX-1, it is possible that at higher concentrations, celecoxib may target COX-1 to some extent (Chan et al., 1999; Warner et al., 1999) . Nonetheless, in the present study, celecoxib was ineffective. Collectively, these data suggest that IgE-dependent PGD 2 generation from human lung mast cells is driven by COX-1.
In further studies, we investigated the effects of COX inhibitors on SCF driven PGD 2 generation from mast cells. Elevated concentrations of the mast cell growth factor, SCF, have been observed in asthma (AlMuhsen et al., 2004; Kowalski et al., 2005; Da Silva et al., 2006 ) and our recent work has shown that SCF is unexpectedly effective at stimulating PGD 2 generation from mast cells (Lewis et al., 2013) . Previous studies have shown that mouse bone marrow derived mast cells express both COX-1 and COX-2 and that whereas IgE-dependent PGD 2 generation mobilises COX-1, cytokine driven PGD 2 generation activates COX-2 (Murakami et al., 1995) . However, in the present study, SCFinduced PGD 2 generation was inhibited effectively by FR122047 whereas celecoxib was ineffective. Overall, these findings suggest that COX-1 is the primary isoform that mediates both IgE-and SCF-dependent PGD 2 generation. These findings strongly support clinical studies showing that COX-1 is likely to be the main driver of PGD 2 generation in asthma (Daham et al., 2011) .
The effects of commonly used NSAIDs on PGD 2 production from human lung mast cells were instructive inasmuch as these compounds are largely considered to be non-selective although data from a number of sources indicate some preference for either COX-1 or COX-2 (Mitchell et al., 1994; Cryer and Feldman, 1998; Chan et al., 1999; Warner et al., 1999) . Selectivity for a given isoform may be dependent on the enzyme system studied. Taking the literature collectively, indomethacin and aspirin appear to be predominantly COX-1 selective, diclofenac is somewhat COX-2 selective, naproxen and ibuprofen overall display only fractional selectivity for one or other isoform. It is of interest that all the NSAIDs studied inhibited PGD 2 generation very effectively with the notable exception of aspirin which was a surprisingly weak inhibitor. The reasons for this are not really apparent. If an assumption is made that COX-1 is the primary isoform present in mast cells then aspirin is at least as potent at COX-1 as some of the other NSAIDs studied such as ibuprofen yet ibuprofen was effective at blocking PGD 2 generation. Why aspirin was relatively ineffective is difficult to understand unless there are issues with aspirin accessing and/or inactivating mast cell COX.
Expression of COX isoforms was determined both by RT-PCR and by Western blotting. Strong mRNA expression was observed for both COX-1 and COX-2. However, at the protein level the picture was somewhat different and it was clearly evident that human lung mast cells strongly express COX-1 and only weakly express COX-2 in the majority of mast cell preparations. These findings are at odds with studies in murine systems as well as cultured human mast cells wherein both COX-1 and COX-2 are thought to co-exist (Murakami et al., 1995; Reddy and Herschman, 1997; Obata et al., 1999) .
Based on previous studies in a mouse mast cell line (Reddy and Herschman, 1997) , the possibility was considered that discrete COX isoforms might be mobilised in a time-dependent fashion. Mast cells were activated for time intervals of 30 min to 4 h with either anti-IgE or SCF. It was of interest that the extent of PGD 2 generation induced by anti-IgE was the same after 30 min or 4 h whereas when SCF was used as a stimulus, over twice as much PGD 2 was generated after 4 h compared to 30 min. These data suggested that SCF can drive PGD 2 generation continuously over at least 4 h.
We considered whether this continuous release of PGD 2 by SCF might be due to the induction of COX-2. However, our data showed that COX-2 levels did not change following longer-term activation of mast cells with SCF. In point of fact a well-recognised inducer of COX-2, LPS, was also investigated to determine whether this would induce COX-2 (Hempel et al., 1994) . However, LPS failed to induce up-regulation of COX-2 in mast cells but readily did so in isolated human lung macrophages. The possibility that SCF might induce PGDS was also considered but, similarly, there was no indication that SCF induced PGDS. Presumably, the nature of the SCF/c-kit interaction transduces signals that permit continuous ongoing activation of the pathway leading to PGD 2 generation.
In the clinical context, these studies may have some bearing on mechanistic aspects related to aspirin-intolerant asthma. Aspirin-intolerant asthma has been shown to be accompanied by increases in cys-LTs and PGD 2 (O'Sullivan et al., 1996; Cahill et al., 2015) . This association with PGD 2 has led to suggestions that aspirin directly activates mast cells by an unidentified mechanism (Steinke et al., 2014) . While the , LPS (100 ng/ml) or SCF (100 ng/ml) and expression of COX-1 and COX-2 evaluated. An MLC preparation was also included. (C) A single mast cell preparation was incubated (20 h) in buffer (control), LPS (100 ng/ml) or SCF (100 ng/ml) and expression of H-PGDS and L-PGDS evaluated. A solubilized mouse brain preparation was also included as a control for L-PGDS. Experiments were performed 3 or more times for (A), (B) and (C). mw stands for molecular weight standards.
possibility exists that mast cells in asthmatic lung or discrete subsets of mast cells found in particular areas of the lung may behave differently in response to aspirin, we were unable to demonstrate that aspirin can activate human lung mast cells directly. Another mechanism that has been forwarded to explain some of the adverse effects of NSAIDs in respiratory conditions is that blocking COX can lead to increased availability of arachidonic acid for metabolism by the lipoxygenase pathway and thereby enhanced generation of cys-LTs (Hamad et al., 2004) . Overall, data in the present study suggested that such a mechanism would be unlikely to occur (see Figs. 2B and 3B) . One reason why a clear enhancement of cys-LT generation was not readily observed may have been related to the fact that, in these experiments, maximally effective concentrations of stimuli were used. It is possible therefore that if optimal levels of cys-LTs were already being generated by a stimulus then there may have been limited opportunity to see any enhancement with a COX inhibitor. For this reason, additional experiments were performed utilising a submaximal concentration of anti-IgE (0.1 µg/ml), 20-fold lower than maximal, to determine whether selected COX inhibitors might enhance cys-LT generation from activated mast cells. Although there was some variability among experiments, overall there was no evidence for enhancement of cys-LTs by COX inhibitors under these conditions (see Fig. S2 , Supporting Information repository). These data are not altogether unexpected since, in other systems, inhibition of COX does not promote increased conversion of arachidonic acid by the lipoxygenase pathway (Sud'ina et al., 2008) . Although not explored in the present study, the possibility that arachidonic acid might also be converted to other active metabolites by alternative pathways cannot be excluded (Feltenmark et al., 2008; Wendell et al., 2014 ).
An alternative possibility that has been put forward to explain aspirin-intolerant asthma is that COX inhibition by aspirin may reduce PGE 2 . Whereas in general PGE 2 is known to have pro-inflammatory effects, paradoxically in the lung, PGE 2 is a bronchodilator and inhibits human lung mast cells (Gauvreau et al., 1999; Hartert et al., 2000; Buckley et al., 2011; Kay et al., 2013) . The loss of an endogenous stabiliser of mast cells in PGE 2 could permit an increase in the release of mast cell derived mediators. If, as we have shown in the present study, aspirin was also ineffective at inhibiting mast cell COX, this might then be reflected by even greater levels of PGD 2 generation. Thus an increased elaboration of PGD 2 by aspirin may reflect an inability to contain PGD 2 generation rather than direct activation of the mast cell.
In summary, we have shown that PGD 2 generation by mast cells is driven by COX-1. We have been unable to demonstrate any supporting role for COX-2. While the possibility cannot be excluded that mast cells in different disease states may behave differently, our findings strongly support the notion that COX-1 is the principal isoform driving PGD 2 from human lung mast cells.
